GSK (GSK) SEC Filings: History & Chart

GSK plc(GSK)

Drug Manufacturers - General · London, GL

$49.24-0.41 (-0.83%)

Delayed quote: Sep 25, 2026, 4:00 PM EDT

About GSK plc

GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.

London, GL

66,841 employees

www.gsk.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Luke Victor Miels

View full financials

Form	Filing Date	Accepted	Document
6-K	Sep 11, 2026	Sep 11, 2026	View filing
6-K	Sep 10, 2026	Sep 10, 2026	View filing
424B2	Sep 10, 2026	Sep 10, 2026	View filing
6-K	Sep 10, 2026	Sep 10, 2026	View filing
6-K	Sep 9, 2026	Sep 9, 2026	View filing
6-K	Sep 9, 2026	Sep 9, 2026	View filing
FWP	Sep 9, 2026	Sep 9, 2026	View filing
424B2	Sep 8, 2026	Sep 8, 2026	View filing
6-K	Sep 8, 2026	Sep 8, 2026	View filing
6-K	Sep 1, 2026	Sep 1, 2026	View filing
6-K	Sep 1, 2026	Sep 1, 2026	View filing
6-K	Aug 26, 2026	Aug 26, 2026	View filing
6-K	Aug 24, 2026	Aug 24, 2026	View filing
6-K	Aug 24, 2026	Aug 24, 2026	View filing
6-K	Aug 24, 2026	Aug 24, 2026	View filing
6-K	Aug 18, 2026	Aug 18, 2026	View filing
SC 13G/A	Aug 13, 2026	Aug 13, 2026	View filing
13F-HR	Aug 13, 2026	Aug 13, 2026	View filing
6-K	Aug 13, 2026	Aug 13, 2026	View filing
6-K	Aug 11, 2026	Aug 11, 2026	View filing
6-K	Aug 3, 2026	Aug 3, 2026	View filing
6-K	Jul 30, 2026	Jul 30, 2026	View filing
6-K	Jul 28, 2026	Jul 28, 2026	View filing
6-K	Jul 28, 2026	Jul 28, 2026	View filing
6-K	Jul 28, 2026	Jul 28, 2026	View filing
6-K	Jul 24, 2026	Jul 24, 2026	View filing
6-K	Jul 24, 2026	Jul 24, 2026	View filing
6-K	Jul 22, 2026	Jul 22, 2026	View filing
6-K	Jul 20, 2026	Jul 20, 2026	View filing
6-K	Jul 17, 2026	Jul 17, 2026	View filing

SEC Filings

Recent Filings